李氏大药厂2023年年报

CONTENTS Corporate Information2Corporate Profile4Financial Highlights7Five-Year Financial Summary9Chairman’s Statement10Management Discussion and Analysis12Directors and Key Personnel Profiles24Report of the Directors32Corporate Governance Report56Independent Auditor’s Report68Consolidated Statement of Profit or Loss77Consolidated Statement of Profit or Loss andOther Comprehensive Income78Consolidated Statement of Financial Position79Consolidated Statement of Changes in Equity81Consolidated Statement of Cash Flows83Notes to the Consolidated Financial Statements85Definition226 Corporate Information BOARD OF DIRECTORS Executive Directors Ms. Lee Siu Fong(Chairman)Ms. Leelalertsuphakun Wanee(Managing Director) James Charles Gale Non-executive Directors Dr. Li XiaoyiMr. James Charles Gale Independent Non-executive Directors Dr. Chan Yau Ching, BobMs. Cheang Yee Wah, Eva(appointed with effect from 17 May 2023)Mr. Lam Yat Cheong(resigned with effect from 17 May 2023)Dr. Tsim Wah Keung, Karl COMPANY SECRETARY Mr. Chow Yiu Ming AUDIT COMMITTEE Dr. Chan Yau Ching, Bob(Chairman)Ms. Cheang Yee Wah, Eva(appointed with effect from 17 May 2023)Mr. Lam Yat Cheong(resigned with effect from 17 May 2023)Dr. Tsim Wah Keung, Karl REMUNERATION COMMITTEE Dr. Tsim Wah Keung, Karl(Chairman)Ms. Leelalertsuphakun WaneeDr. Chan Yau Ching, Bob NOMINATION COMMITTEE Ms. Lee Siu Fong(Chairman)Dr. Chan Yau Ching, BobDr. Tsim Wah Keung, Karl MANAGEMENT COMMITTEE Ms. Leelalertsuphakun Wanee(Chairman)Ms. Lee Siu Fong AUDITOR Confucius International CPA LimitedCertified Public Accountants LEGAL ADVISERS King & Wood Mallesons(Hong Kong law)Beijing Wuhuan Law Firm(PRC law) REGISTERED OFFICE PO Box 309Ugland House, Grand CaymanKY1-1104, Cayman Islands PO Box 309Ugland House, Grand CaymanKY1-1104, Cayman Islands PLACE OF BUSINESS IN HONG KONG 1/F, Building 20E, Phase 3Hong Kong Science Park, ShatinHong Kong 20E HONG KONG SHARE REGISTRAR ANDTRANSFER OFFICE 183171712–1716 Computershare Hong Kong Investor Services LimitedShops 1712–1716, 17th Floor, Hopewell Centre183 Queen’s Road East, WanchaiHong Kong AUTHORISED REPRESENTATIVES Ms. Lee Siu FongMs. Leelalertsuphakun Wanee www.leespharm.com WEBSITE www.leespharm.com STOCK CODE 950 950 Corporate Profile The Company is a research-driven and market-oriented biopharmaceuticalcompany with more than 25 years of operation in the pharmaceuticalindustry in China. TheGroup is fully integrated with solid infrastructures in drugdevelopment, clinical development, regulatory, manufacturing, salesand marketing based in Mainland China with global perspectives. TheGroup has established extensive partnerships with over 20 internationalcompanies and currently markets over 25 proprietary, generic andlicensed-in pharmaceutical products in Mainland China, Hong Kong, Macauand Taiwan. The Group focuses on several key disease areas such as cardiovascular,woman health, paediatrics, rare diseases, oncology, dermatology andobstetrics. It has more than 40 products under different developmentstages stemming from both internal research and development as well asfrom the licensing of development, commercialisation, and manufacturingrights from various United States, European and Japanese companies. The Group carries out its sales and distribution activities in Hong Kong,Macau, Taiwan and Mainland China through Hong Kong and Taiwan officesand branch offices in Chongqing, Guangzhou, Shanghai and Beijing withdirect and channel sales network covering most of the provinces and citiesin Mainland China, marketing both domestic self-developed and genericproducts and overseas licensed-in products. The Group has just establishedan office in Thailand with the intention of conducting sales and distributionactivities within the Thai market in the near future. Zhaoke Hefei, iscurrently operating the manufacturing plant of the Group located in Hefei,Anhui Province of the PRC, comprising four GMP-compliant workshopsfor the production of topical gel, lyophilised powder for injection, smallvolume parenteral solutions and eye gel. Zhaoke Guangzhou, is currentlyoperating the manufacturing site in Nansha District, Guangzhou of the PRCwhich include a complete range of solid dosage production lines for thedevelopment and manufacturing of tablets and capsules. GMP The mission of the Group is to become a successful biopharmaceuticalgroup in Asia providing innovative products to fight diseases and improvehealth and quality of life. Corporate Profile *Apremilast TabletsPRC®*Azilsartan TabletsPRC®*Fondaparinux SodiumInjectionPRC®Sodium PhenylbutyrateGranulesPRC®*Treprostinil InjectionPRC® Financial Highlights Financial Highlights PROFIT ATTRIBUTABLE TO THEOWNERS OF THE COMPANY(HK$’000) EQUITY ATTRIBUTABLE TO THEOWNERS OF THE COMPANY(HK$’000) BASIC EARNINGS PER SHARE(HK CENTS) Five-Year Financial Summary Chairman’s Statement Dear Shareholders, On behalf of the Company and Board, I hereby present the a